Omega Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kaan Certel
- Full Time Employees
- 93
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 20 Acorn Park Drive Cambridge MA United States of America 02140
- IPO Date
- Jul 30, 2021
- CIK
- 0001850838
- Website
- omegatherapeutics.com
- Similar Companies
- Business
- Omega Therapeutics, Inc. (NASDAQ: OMGA) is a clinical-stage biotechnology company that develops programmable epigenomic mRNA medicines, known as Omega Epigenomic Controllers (OECs), using its proprietary OMEGA platform to precisely control gene expression by modulating fundamental epigenetic processes within insulated genomic domains. The company's core pipeline includes OTX-2002, an OEC targeting c-MYC for hepatocellular carcinoma and other MYC-driven solid tumors; programs in oncology, fibrosis, and neurological disorders such as alopecia; and prioritized preclinical initiatives in obesity, regenerative medicine, and metabolic indications leveraging epigenomic modulation for trans-differentiation, durable gene upregulation, and multiplexed control. The OMEGA platform integrates advanced data science, rational drug design, and lipid nanoparticle delivery to engineer modular mRNA-based controllers that restore aberrant gene expression without altering native DNA sequences. Founded in 2017 and headquartered in Cambridge, Massachusetts, Omega Therapeutics operates primarily in the United States with a focus on genomic medicine across oncology, regenerative medicine, and metabolic disease segments, targeting patients with diseases driven by dysregulated gene expression. The company serves pharmaceutical partners and healthcare providers through its therapeutic candidates and collaboration agreements. In November 2024, Omega announced successful topline data from the Phase 1 MYCHELANGELO I trial of OTX-2002, demonstrating proof-of-mechanism with specific on-target epigenomic state changes, favorable safety including manageable infusion-related reactions, and predictable pharmacokinetics in hepatocellular carcinoma patients. Recent strategic shifts include pipeline prioritization on three epigenomic programs in obesity, regenerative medicine, and metabolic areas; appointment of Jennifer Nelson, Ph.D., as Chief Scientific Officer; and active pursuit of strategic partnerships for Phase 2 development of OTX-2002 and pipeline expansion. Earlier developments encompass a clinical supply agreement with F. Hoffmann-La Roche Ltd. to evaluate OTX-2002 combined with atezolizumab; a collaboration with Novo Nordisk on an obesity therapeutic providing up to $532 million in milestones and royalties; and a $1.26 billion Series C financing in March 2024 to advance OTX-2002 and platform capabilities. In February 2025, the company filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware to support ongoing operations and strategic objectives.
Omega Pacific Closes First Tranche of Non-Brokered Private Placement
Omega Pacific Clarifies Size of Previously Announced Private Placement
Omega Pacific Announces Non-Brokered Private Placement
Omega Pacific Acquires 100% of Williams Property
Omega Pacific Closes Non-Brokered Private Placement
Omega Pacific Closes First Tranche of Offering
Omega Pacific Announces Private Placement
Omega Pacific Outlines 2025 Exploration Program in the Revitalized Toodoggone District
Omega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams Property
Omega Pacific Announces 2024 Work Program Results From Its Lekcin Property
Omega Therapeutics, Inc. (OMGA) Reports Q3 Loss, Tops Revenue Estimates
Omega Pacific Earns 51% Interest in Williams Property
Omega Pacific Adds John Williamson as Independent Director
Omega Pacific Extends Historical Hole WM22-02 Mineralization to 2.16 G/t Au Over 96.92 Metres
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
Omega Pacific Issues Common Shares for Three Additional Claims in the Golden Horseshoe Area in British Columbia
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
Omega Pacific Intersects Three Separate Gold Zones Demonstrating Bulk-Tonnage Gold Mineralization at its Williams Property
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates